Lisa McGregor, MD, PhD - Penn State Cancer Institute
Researcher Profile
Lisa McGregor, MD, PhD
Howard O. Jr. and Jean S. Beaver Professor of Pediatric Hematology/Oncology, Department of Pediatrics
Chief, Division of Hematology and Oncology
Division of Hematology and Oncology
Chief, Division of Hematology and Oncology
Division of Hematology and Oncology
Scientific Program:Next-Generation Therapies
Disease Teams:
Cancer Institute, Pediatric Cancer Team
Clinical Trials
A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
Phase II Trial of Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma BCC022
NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)
A Phase 1/2, Open-label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects with Advanced or Metastatic Malignancies Harboring ALK, ROS1, or NTRK1-3 Alterations (CARE)
A Randomized Phase 3 trial of Nivolumab (NSC# 748726 IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma
A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor
A Dose Escalation Study Using Difluoromethylornithine (DFMO) and AMXT-1501 followed by a Randomized Controlled Trial of DFMO with or without AMXT-1501 for Neuroblastoma, CNS Tumors, and Sarcomas
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
A Phase II Study of Naxitamab Added to Induction Therapy for Subjects with Newly Diagnosed
High-Risk Neuroblastoma
BCC021 Phase I/II study of Silmitasertib (CX-4945) in combination with chemotherapy in children and young adults with relapsed refractory solid tumors
Renal Tumor Classification, Biology, and Banking Study
Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
A Phase 3 Randomized Study of Selumetinib (IND # 77782) versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
Umbrella Long-term Follow-up Protocol
A Phase 2 Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) after Local Irradiation in Newly-Diagnosed BRAFV600-Mutant High-Grade Glioma (HGG) (IND# 145355)
A Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor (MUD) versus HLA-Haploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults (AYA) with Acute Leukemia or Myelodysplastic Syndrome (MDS) ASCT2031
AHOD2131 A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
The Project: Every Child Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
A Pilot Study Using Molecular Guided Therapy with Induction Chemotherapy Followed by Maintenance with DFMO for Subjects with Newly Diagnosed High-Risk Neuroblastoma
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
AGCT1532, Randomized Phase 3 Trial of Accelerated vs Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastic Germ Cell Tumors
Recent Publications
2024
Caru, M, Dandekar, S, Gordon, B, Conroy, DE, Barb, ED, Doerksen, SE, Smink, GM, McKeone, DJ, Shah, NB, Greiner, RJ, Schramm, JW, Rao, P, McGregor, L & Schmitz, KH 2024, 'Implementing a behavioral physical activity program in children and adolescent survivors of childhood cancer: a pilot randomized controlled trial', Journal of Behavioral Medicine, vol. 47, no. 5, pp. 792-803. https://doi.org/10.1007/s10865-024-00497-z
2023
Caru, M, Alberts, NM, Freeman, MC, Dandekar, SC, Rao, P, McKeone, DJ, Brown, VI, McGregor, LM & Schmitz, KH 2023, 'Chronic pain in children and adolescents diagnosed with cancer: the challenge of mitigating the pain and the potential of integrating exercise into pain management', Supportive Care in Cancer, vol. 31, no. 4, 228. https://doi.org/10.1007/s00520-023-07695-6
2022
Caru, M, Levesque, A, Rao, P, Dandekar, S, Terry, C, Brown, V, McGregor, L & Schmitz, K 2022, 'A scoping review to map the evidence of physical activity interventions in post-treatment adolescent and young adult cancer survivors', Critical Reviews in Oncology/Hematology, vol. 171, 103620. https://doi.org/10.1016/j.critrevonc.2022.103620
2020
Santana, VM, Sahr, N, Tatevossian, RG, Jia, S, Campagne, O, Sykes, A, Stewart, CF, Furman, WL & McGregor, LM 2020, 'A phase 1 trial of everolimus and bevacizumab in children with recurrent solid tumors', Cancer, vol. 126, no. 8, pp. 1749-1757. https://doi.org/10.1002/cncr.32722
Rao, P, Segel, JE, McGregor, LM, Lengerich, EJ, Drabick, JJ & Miller, B 2020, 'Attendance at National Cancer Institute and Children's Oncology Group Facilities for Children, Adolescents, and Young Adults with Cancer in Pennsylvania: A Population-Based Study', Journal of Adolescent and Young Adult Oncology, vol. 9, no. 1, pp. 47-54. https://doi.org/10.1089/jayao.2019.0045